Cargando…
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study
BACKGROUND: The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes...
Autores principales: | Henry, N L, Pchejetski, D, A'Hern, R, Nguyen, A T, Charles, P, Waxman, J, Li, L, Storniolo, A M, Hayes, D F, Flockhart, D A, Stearns, V, Stebbing, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920022/ https://www.ncbi.nlm.nih.gov/pubmed/20606683 http://dx.doi.org/10.1038/sj.bjc.6605768 |
Ejemplares similares
-
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
por: Henry, N L, et al.
Publicado: (2013) -
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016) -
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
por: Gaillard, Stéphanie, et al.
Publicado: (2011) -
Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms
por: Henry, N Lynn, et al.
Publicado: (2021) -
Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
por: Khan, Qamar J., et al.
Publicado: (2010)